CC BY 4.0 · Pharmaceutical Fronts 2020; 02(04): e168-e178
DOI: 10.1055/s-0041-1726301
Original Article

Serum Pharmacochemistry Analysis Combined with Network Pharmacology Approach to Investigate the Antiosteoporosis Effect of Xianlinggubao Capsule in vivo

Yun-Hui Xu#
1  State Key Lab. of New Drug and Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai, People's Republic of China
,
Yi-Chun Sun#
2  Sinopharm Group Tongjitang (Guizhou) Pharmaceutical Co., Ltd., Guiyang, People's Republic of China
3  Guangdong Efong Pharmaceutical Co., Ltd, Guangzhou, People's Republic of China
,
Jie Liu
1  State Key Lab. of New Drug and Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai, People's Republic of China
,
Hui-Xin Li
2  Sinopharm Group Tongjitang (Guizhou) Pharmaceutical Co., Ltd., Guiyang, People's Republic of China
,
Chun-Yue Huang
1  State Key Lab. of New Drug and Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai, People's Republic of China
,
Yuan-Yuan Pang
2  Sinopharm Group Tongjitang (Guizhou) Pharmaceutical Co., Ltd., Guiyang, People's Republic of China
,
Tong Wu#
1  State Key Lab. of New Drug and Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai, People's Republic of China
,
Xiao Hu#
1  State Key Lab. of New Drug and Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai, People's Republic of China
2  Sinopharm Group Tongjitang (Guizhou) Pharmaceutical Co., Ltd., Guiyang, People's Republic of China
› Author Affiliations
Funding Statement This research was funded by the Project of Standardization of Chinese Materia Medica (Grant No. ZYBZH-C-GZ-10), China Postdoctoral Science Foundation (Grant No. 2018M633022), and National Science and Technology Major Project (Grant No. 2018ZX09731-016).

Abstract

Xianlinggubao capsule (XLGB) is a traditional Chinese medicine multi-component herbal prescription and has been widely used in osteoporosis (OP) treatment. However, the underlying anti-OP mechanisms of XLGB have not been fully studied. In this study, an ovariectomized rat model of OP was established. The OP rats were orally administrated with XLGB, and then the main absorbed components in serum sample were assessed based on liquid chromatography-tandem mass spectrometry (LC-MS/MS). Subsequently, the potential anti-OP markers in XLGB were screened based on a network pharmacology strategy. Molecular docking analysis was used for confirmation. LC-MS showed 22 absorbed components in the serum sample of OP rat with XLGB treatment. Network pharmacology and pathway analysis suggested 19 potential anti-OP markers in XLGB. According to molecular docking process, most of the potential markers displayed strong interactions with the 22 absorbed components mentioned above. Besides, an absorbed component–potential marker–pathway network was further established. In conclusion, our data suggested the possible mechanisms for XLGB in OP treatment, in which the “multicomponents, multitargets, and multipathways” participated. Our article provided possible direction for drug discovery in OP and could help for exploring novel application of XLGB in clinical setting.

Author Contributions

Xiao Hu designed the experiments and checked the final manuscript. Yun-Hui Xu performed the experiments, analyzed and interpreted the results, and wrote the manuscript. Yi-Chun Sun performed some experiments, contributed materials, and checked the data. Jie Liu searched the relevant literature. Hui-Xin Li, Chun-Yue Huang, and Yuan-Yuan Pang provided helpful discussions. Tong Wu directed the research. All authors have read and approved the final version of this manuscript.


# These authors contributed equally to this work.


Supplementary Material



Publication History

Received: 28 December 2020

Accepted: 10 February 2021

Publication Date:
08 April 2021 (online)

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany